Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19.

ABSTRACT:

Background

The incidence of elevated liver chemistries and the presence of pre-existing chronic liver disease (CLD) have been variably reported in COVID-19.

Aims

To assess the prevalence of CLD, the incidence of elevated liver chemistries and the outcomes of patients with and without underlying CLD/elevated liver chemistries in COVID-19.

Methods

A comprehensive search of electronic databases from 1 December 2019 to 24 April 2020 was done. We included studies reporting underlying CLD or elevated liver chemistries and patient outcomes in COVID-19.

Results

107 articles (n = 20 874 patients) were included for the systematic review. The pooled prevalence of underlying CLD was 3.6% (95% CI, 2.5-5.1) among the 15 407 COVID-19 patients. The pooled incidence of elevated

SUBMITTER: Kulkarni AV 

PROVIDER: S-EPMC7361465 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature